Daily Sepsis Research Analysis
Analyzed 39 papers and selected 3 impactful papers.
Summary
Today's most impactful sepsis research spans rapid diagnostics, mechanistic immunometabolism, and paradigm-challenging pathophysiology. A prospective NICU study shows that melting temperature mapping accelerates pathogen identification and detects clinically relevant cases missed by blood culture. Mechanistically, LDHB K156 lactylation links cGAS–STING-driven metabolic reprogramming to NLRP3 activation in sepsis-associated AKI, while LC–MS/MS quantification reveals no elevation of plasma LPS in severe pneumonia/COVID-19, questioning the gut endotoxemia hypothesis.
Research Themes
- Rapid diagnostics in neonatal sepsis
- Immunometabolic mechanisms and lactylation in sepsis-associated AKI
- Revisiting endotoxemia in severe pneumonia/COVID-19 using mass spectrometry
Selected Articles
1. LDHB K156 lactylation links cGAS-STING-mediated metabolic reprogramming to NLRP3 inflammasome activation in sepsis-associated acute kidney injury.
Using CLP mice and LPS-stimulated HK-2 cells, the authors show that sepsis drives glycolysis and lactate accumulation, upregulating LDHB K156 lactylation. Upstream cGAS–STING signaling promotes this metabolic reprogramming, while the EP300/HDAC2 axis regulates LDHB K156 lactylation. In vivo, renal tubule expression of WT LDHB worsened renal dysfunction and NLRP3 activation versus the K156R mutant, identifying a targetable mechanism in SA-AKI.
Impact: This work uncovers a previously unrecognized non-histone lactylation node (LDHB K156) that mechanistically links innate immune sensing to inflammasome-driven kidney injury, offering a precise, druggable axis.
Clinical Implications: Although preclinical, targeting LDHB K156 lactylation or its regulators (EP300/HDAC2, cGAS–STING) could attenuate inflammatory amplification in SA-AKI and guide biomarker development for patient stratification.
Key Findings
- Sepsis increased glycolysis, lactate accumulation, and NLRP3 inflammasome activation in CLP mice and LPS-stimulated HK-2 cells.
- Lactyl-proteomics identified marked upregulation of LDHB K156 lactylation.
- Upstream cGAS–STING signaling drove glycolytic reprogramming and provided substrates for LDHB K156 lactylation, regulated by the EP300/HDAC2 axis.
- AAV-mediated renal tubule expression of LDHB WT exacerbated renal dysfunction, histologic injury, and inflammasome activation compared with the lactylation-deficient K156R mutant.
Methodological Strengths
- Integrated in vivo (CLP) and in vitro (HK-2) models with lactyl-proteomic screening
- Causal validation via renal tubule–specific AAV expression of WT versus lactylation-deficient LDHB
Limitations
- Preclinical study without human tissue validation
- Therapeutic modulation of the pathway was not tested for efficacy in vivo beyond genetic constructs
Future Directions: Validate LDHB K156 lactylation in human SA-AKI, develop pharmacologic modulators (e.g., EP300/HDAC2 or cGAS–STING inhibitors), and test renoprotective efficacy in translational models.
AIMS: Sepsis-associated acute kidney injury (SA-AKI) pathogenesis remains incompletely understood. This study aimed to elucidate the immunometabolic mechanisms driving SA-AKI, focusing on the role of metabolic reprogramming and non-histone protein lactylation in amplifying renal inflammation. MATERIALS AND METHODS: We utilized a cecal ligation and puncture (CLP) mouse model and lipopolysaccharide (LPS)-stimulated HK-2 cells. Evaluations included lactyl-proteomic screening, cellular metabolic/biochemical assays, and in vivo adeno-associated virus (AAV)-mediated renal tubule-specific expression of wild-type (WT) or lactylation-deficient mutant (K156R) lactate dehydrogenase B (LDHB). KEY FINDINGS: Sepsis induced pronounced glycolysis, lactate accumulation, and NLRP3 inflam
2. Melting temperature mapping for rapid pathogen identification in neonatal bloodstream infections: A prospective study.
In a prospective NICU study of 321 samples (248 patients), Tm mapping identified pathogens faster than blood culture in all six culture-positive cases and supported clinical diagnosis in three culture-negative sepsis cases. While polymicrobial samples caused some species discrepancies, results aligned with clinical courses. Among Tm-negative samples, 10 were culture-positive (four true bacteremias, six contaminants).
Impact: This study evaluates a culture-independent, rapid PCR-based method directly in NICU practice, demonstrating earlier actionable identification and complementary value to blood culture.
Clinical Implications: Tm mapping could enable earlier targeted antibiotics and improved antimicrobial stewardship in neonatal sepsis by complementing culture, though integration should consider polymicrobial discordance and false negatives.
Key Findings
- Tm mapping identified bacteria in 26/321 samples; all six culture-positive cases were detected earlier by Tm mapping.
- Three culture-negative cases were diagnosed as sepsis based on Tm mapping results and clinical course.
- Of 295 Tm-negative samples, 10 were culture-positive; four were true bacteremias and six were contaminants.
- Species discrepancies occurred in polymicrobial infections, yet overall results were consistent with clinical courses.
Methodological Strengths
- Prospective design with head-to-head comparison against blood culture in a real-world NICU setting
- Low sample volume (mean 261 μL) suitable for neonates with timely (≤4 h) turnaround
Limitations
- Single-center study with a modest number of positive cases
- Species-level discrepancies in polymicrobial samples and missed pathogens in Tm-negative cases
Future Directions: Conduct multicenter validation with standardized workflows, assess impact on time-to-appropriate therapy and outcomes, and refine panels/algorithms for polymicrobial detection.
BACKGROUND: The melting temperature (Tm) mapping method is a culture-independent diagnostic tool for the early detection of bloodstream infections, utilizing real-time polymerase chain reaction. It identifies 163 bacterial species and quantifies bacterial load within 4 h of sample collection. This study aimed to evaluate its clinical utility in a neonatal intensive care unit (NICU). METHODS: This single-center prospective study was conducted at the Toyama University Hospital NICU (2019-2024). Blood samples were collected from neonates diagnosed with or suspe
3. Endotoxemia and its association with immune and coagulopathy responses in severe community-acquired pneumonia and COVID-19.
Using a validated LC–MS/MS assay, plasma LPS levels were lower in severe CAP and severe COVID-19 than in healthy controls and did not correlate with severity scores or mortality. Only low positive correlations were seen with sVCAM-1 and D-dimer, and higher LPS did not translate into thrombotic risk. These findings challenge the concept that gut-derived endotoxemia is a major driver of systemic inflammation in severe pneumonia.
Impact: By overcoming assay limitations with mass spectrometry, this study provides high-specificity evidence that contradicts a prevalent endotoxemia hypothesis, redirecting mechanistic and therapeutic focus.
Clinical Implications: Findings argue against LPS-neutralizing strategies in severe pneumonia/COVID-19 and support prioritizing alternative inflammatory or endothelial pathways and refined biomarker panels.
Key Findings
- Plasma LPS concentrations were significantly lower in severe CAP and severe COVID-19 than in healthy volunteers.
- LPS levels did not correlate with severity scores or mortality.
- Only low positive correlations were observed with endothelial activation (sVCAM-1) and coagulation (D-dimer) markers.
- Patients with higher LPS did not show increased thrombotic or cardiovascular events.
Methodological Strengths
- Prospective design with matched healthy controls and comprehensive biomarker profiling
- Validated LC–MS/MS quantification of LPS (lipid A 3-hydroxy fatty acids) overcoming immunoassay limitations
Limitations
- Modest sample size and single-cohort ancillary design
- Single timepoint sampling limits assessment of temporal dynamics
Future Directions: Undertake multicenter studies with serial sampling, explore mechanisms underlying lower LPS levels, and reassess endotoxin-targeted interventions in light of precise quantification.
BACKGROUND: Acute community-acquired pneumonia (CAP) is a leading cause of infection-related mortality worldwide. Endotoxemia, characterized by elevated plasma lipopolysaccharide (LPS), is a key driver of inflammation and thrombosis in Gram-negative sepsis and has been suggested to occur in severe pneumonia, irrespective of etiology. However, current immunoassays for LPS quantification lack sensitivity and specificity. We aimed to quantify plasma LPS in severe CAP patients, including COVID-19, using a validated mass spectrometry method, and to explore associations with immune activation, coagulation, gut translocation, and clinical outcomes. METHODS: In this prospective ancillary study of the LYMPHONIE cohort, we included 34 non-COVID-19 severe CAP (sCAP), 34 severe COVID-19 (sCOVID-19) and 34 matched healthy volunteers. Plasma LPS was measured by LC-MS/MS detecting 3-hydroxy fatty acids of lipid A. Clinical data, immune biomarkers, coagulation biomarkers, and gut injury markers were measured. RESULTS: Unexpectedly, median plasma LPS concentrations were signific